BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, May 4, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Oct. 6, 2003
View Archived Issues
Cubist Signs Chiron As Ex-U.S. Partner For Cubicin Marketing
Read More
Ariad Gets $41M In Private Sale For Drug Development
Read More
Ligand Pulls Down $12.5M Through Royalty Agreement
Read More
Flamel Raises $62M Through Sale Of Its Common Shares
Read More
Receptor BioLogix Steering Lead Product Toward Gastric Cancer
Read More
Other News To Note
Read More
Asking For More Data, FDA Places Hold On DOV's Ocinaplon Phase III
The FDA placed a hold on DOV Pharmaceutical Inc.'s pivotal Phase III trial for an anti-anxiety candidate, asking for additional safety data. (BioWorld Today)
Read More